2 Year COMPASS Trial Results: Supraciliary Microstenting wit
Evaluation of 2-year safety and efficacy of supraciliary microstenting for treating mild-to-moderate primary open-angle glaucoma (POAG) in patients undergoing cataract surgery. / Methodology - After completing cataract surgery, subjects were intraoperatively randomized to phacoemulsification only (control) or supraciliary microstenting with phacoemulsification (microstent) groups (1:3 ratio). Microstent implantation via an ab interno approach to the supraciliary space allowed concomitant cataract and glaucoma surgery. Conclusion - This RCT demonstrated safe and sustained 2-year reduction in IOP and glaucoma medication use after microinterventional surgical treatment for mild-to-moderate POAG...

http://www.aaojournal.org/article/S0161-6420(16)30500-0/fulltext
Like
Comment
Share